Sponsor: Dana-Farber Cancer Institute - DFCI
Sponsor Study ID: 20-166
Study Title: Randomized Phase 2 Trial of Sacituzumab Govitecan With or Without Pembrolizumab in First-line Metastatic PD-L1-negative TNBC
CTO #: 104165
NCT Number: NCT04468061
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Breast
Study Objectives: To compare the progression free survival of sacituzumab govitecan with pembrolizumab to that of sacituzumab govitecan alone in patients with PD-L1 negative metastatic TNBC, who have not recieved prior thereapy for metastatic breast cancer and who have not recieved a prior PD-1/L1 inhibitor.